Quantcast
Last updated on April 24, 2014 at 11:09 EDT

Latest Chimeric antigen receptor Stories

2014-04-03 08:22:27

DUBLIN, Apr. 03, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/gw6znv/the_engineered ) has announced the addition of the "The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry" report to their offering. (Logo:http://photos.prnewswire.com/prnh/20130307/600769) A Comparative Analysis And Assessment Of TCR Technologies, Pipelines And Companies From An Industry Perspective...

2014-03-17 08:29:24

NCI study to investigate whether third generation CAR T Cells can be eliminated if they become harmful HOUSTON, March 17, 2014 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. announced today that the first clinical study is underway of a Chimeric Antigen Receptor (CAR) T Cell therapy that incorporates a safety switch to enable rapid elimination of the administered T cells if they threaten the life or health of the patient. Researchers from the National Cancer Institute (NCI) have...

2014-02-18 08:30:40

LONDON, Feb. 18, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical IndustryA comparative analysis and assessment of TCR technologies, pipelines and companies from an industry perspectiveTherapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an...

2013-12-12 12:26:31

MUMBAI, December 12, 2013 /PRNewswire/ -- A comparative analysis and assessment of TCR technologies, pipelines and companies from an industry perspective Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average (continuous) annual growth rate from 2006 to 2012 of 18.9%. While antibody technologies are steadily evolving, the spectrum of drug gable targets for monoclonal...

2013-12-07 16:20:24

- Findings Presented at 55th American Society of Hematology (ASH) Annual Meeting - LOS ANGELES, Dec. 7, 2013 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on engineered autologous T cell therapy (eACT) products for cancer, today announced positive clinical data demonstrating that Kite's most advanced product candidate can produce robust and durable tumor shrinkage in patients with an aggressive form of non-Hodgkin's lymphoma. In an oral...

2013-12-07 08:20:47

-- Data at ASH show increased scientific understanding of CTL019 and its potential role in the treatment of certain types of lymphocytic leukemia(1,2,3,4) EAST HANOVER, N.J., Dec. 7, 2013 /PRNewswire/ -- Novartis is highlighting new research from members of the faculty at the University of Pennsylvania's Perelman School of Medicine (Penn) on the investigational chimeric antigen receptor (CAR) therapy, CTL019. Several studies being presented at the American Society of Hematology (ASH) annual...

2013-07-31 08:30:10

Life Technologies' proprietary Dynabeads®CD3/CD28 CTS(TM) utilized to isolate, activate and expand therapeutic T cells for oncology indications CARLSBAD, Calif., July 31, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced that the company has signed a long-term supply and exclusive licensing agreement with Novartis for immunotherapeutics involving T cells modified to express chimeric antigen receptors for the treatment of cancer. Life Technologies...

2013-03-25 12:27:13

-- CHOP/Penn Medicine Oncology Team Reports Complete Remission in Pediatric ALL Patients PHILADELPHIA, March 25, 2013 /PRNewswire-USNewswire/ -- Two children with an aggressive form of childhood leukemia had a complete remission of their disease--showing no evidence of cancer cells in their bodies--after treatment with a novel cell therapy that reprogrammed their immune cells to rapidly multiply and destroy leukemia cells. A research team from The Children's Hospital of...

2013-03-19 12:28:01

MEMPHIS, Tenn., March 19, 2013 /PRNewswire-USNewswire/ -- The United States Patent and Trademark Office today awarded St. Jude Children's Research Hospital U.S. patent number 8,399,645 for St. Jude's invention of compositions for genetically modifying human immune cells so they can destroy some of the most common forms of cancer in children and adults. "This groundbreaking invention enables human immune cells to recognize and attack certain cells that cause leukemia and lymphoma, cancers...

2012-12-09 20:20:19

University of Pennsylvania Researchers Report on Results of Trial in 12 Patients, Including Two Children ATLANTA, Dec. 9, 2012 /PRNewswire-USNewswire/ -- Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the Perelman School of Medicine at the University of Pennsylvania. Penn Medicine researchers will present the latest...